
Annual report 2024
added 02-14-2026
GlaxoSmithKline plc EPS Ratio 2011-2026 | GSK
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio GlaxoSmithKline plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 0.876 | 1.16 | 0.939 | 0.737 | 0.314 | 0.188 | 1.74 | - | - | - | - |
All numbers in GBP currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.74 | 0.188 | 0.85 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Biotechnology industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-15.4 | - | 2.43 % | $ 254 M | ||
|
Amarin Corporation plc
AMRN
|
-0.15 | $ 14.81 | -0.34 % | $ 6.04 B | ||
|
Acer Therapeutics
ACER
|
-1.66 | - | 2.71 % | $ 14 M | ||
|
Acasti Pharma
ACST
|
-0.79 | - | 4.01 % | $ 150 M | ||
|
I-Mab
IMAB
|
-7.66 | - | - | $ 866 M | ||
|
Adverum Biotechnologies
ADVM
|
-6.62 | - | - | $ 86.2 M | ||
|
Legend Biotech Corporation
LEGN
|
-1.37 | $ 17.8 | -1.44 % | $ 18.7 B | ||
|
Anavex Life Sciences Corp.
AVXL
|
-0.54 | $ 3.93 | 0.26 % | $ 335 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | ||
|
Adagene
ADAG
|
-0.59 | $ 3.24 | 13.85 % | $ 182 M | ||
|
Biophytis SA
BPTS
|
-0.26 | - | -13.47 % | $ 169 M | ||
|
Akouos
AKUS
|
-2.52 | - | 0.23 % | $ 488 M | ||
|
Aptorum Group Limited
APM
|
-0.78 | $ 0.79 | -7.27 % | $ 4.31 M | ||
|
AlloVir
ALVR
|
-11.7 | - | 4.14 % | $ 49.1 M | ||
|
Midatech Pharma plc
MTP
|
-31 | - | -18.52 % | $ 27.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-10.7 | - | -11.43 % | $ 502 K | ||
|
Alterity Therapeutics Limited
ATHE
|
-0.53 | $ 3.48 | -0.98 % | $ 8.37 B | ||
|
Applied Molecular Transport
AMTI
|
-3.25 | - | - | $ 10.1 M | ||
|
ARCA biopharma
ABIO
|
-3.87 | - | 1052.0 % | $ 415 M | ||
|
Biogen
BIIB
|
8.83 | $ 195.63 | 0.06 % | $ 28.7 B | ||
|
Acorda Therapeutics
ACOR
|
-204 | - | -24.86 % | $ 820 K | ||
|
Aptose Biosciences
APTO
|
-36.4 | - | -45.71 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
-3.75 | - | - | $ 3.67 B | ||
|
Athira Pharma
ATHA
|
-2.52 | - | - | $ 269 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-24.9 | - | - | $ 1.01 B | ||
|
Albireo Pharma
ALBO
|
-1.77 | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
-0.72 | - | 3.16 % | $ 1.9 M | ||
|
Ascendis Pharma A/S
ASND
|
-8.28 | $ 216.28 | -0.83 % | $ 5 B | ||
|
Bristol-Myers Squibb Company
BMY
|
3.47 | $ 60.51 | 1.12 % | $ 123 B | ||
|
Aptinyx
APTX
|
-0.96 | - | -39.0 % | $ 4.57 M | ||
|
Aravive
ARAV
|
-2.1 | - | -13.39 % | $ 1.45 M | ||
|
Arena Pharmaceuticals
ARNA
|
-10.1 | - | -6.81 % | $ 3.04 B | ||
|
BioNTech SE
BNTX
|
42.2 | $ 106.24 | 0.45 % | $ 27.2 B | ||
|
Aridis Pharmaceuticals
ARDS
|
-1.62 | - | 17.91 % | $ 11.1 M | ||
|
Aeterna Zentaris
AEZS
|
-0.07 | - | 5.93 % | $ 314 M | ||
|
Brickell Biotech
BBI
|
-1.06 | - | -5.38 % | $ 6.06 M | ||
|
AgeX Therapeutics
AGE
|
-13.7 | - | -10.17 % | $ 12.2 K | ||
|
Athersys
ATHX
|
-0.39 | - | 3.77 % | $ 22.4 M | ||
|
Avenue Therapeutics
ATXI
|
-15.8 | - | -52.27 % | $ 4.45 M | ||
|
BeiGene, Ltd.
BGNE
|
-0.47 | - | 0.49 % | $ 251 B | ||
|
Autolus Therapeutics plc
AUTL
|
-0.86 | $ 1.41 | 1.81 % | $ 360 M | ||
|
Burford Capital Limited
BUR
|
75.3 | $ 9.33 | 0.32 % | $ 1.51 B | ||
|
Amneal Pharmaceuticals
AMRX
|
-0.38 | $ 14.8 | 1.13 % | $ 4.57 B | ||
|
AIkido Pharma
AIKI
|
-2.38 | - | 1.93 % | $ 17.4 M | ||
|
AVROBIO
AVRO
|
0.27 | - | 1083.1 % | $ 745 M | ||
|
CureVac N.V.
CVAC
|
-2.21 | - | - | $ 867 M | ||
|
Alpine Immune Sciences
ALPN
|
-1.73 | - | - | $ 2.17 B |